WallStSmart

Merck & Company Inc (MRK)vsWW International, Inc (WW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 9903% more annual revenue ($66.57B vs $665.49M). MRK leads profitability with a 4.8% profit margin vs -15.2%. MRK appears more attractively valued with a PEG of 2.64. WW earns a higher WallStSmart Score of 39/100 (F).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

WW

Hold

39

out of 100

Grade: F

Growth: 2.0Profit: 5.0Value: 5.7Quality: 6.0
Piotroski: 5/9Altman Z: 5.10
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued

Intrinsic value data unavailable for WW.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

WW4 strengths · Avg: 10.0/10
P/E RatioValuation
1.6x10/10

Attractively priced relative to earnings

Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Return on EquityProfitability
405.4%10/10

Every $100 of equity generates 405 in profit

Altman Z-ScoreHealth
5.1010/10

Safe zone — low bankruptcy risk

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

WW4 concerns · Avg: 2.5/10
Market CapQuality
$180.18M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.533/10

Elevated debt levels

PEG RatioValuation
4.922/10

Expensive relative to growth rate

Revenue GrowthGrowth
-14.2%2/10

Revenue declined 14.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : WW

The strongest argument for WW centers on P/E Ratio, Price/Book, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : WW

The primary concerns for WW are Market Cap, Debt/Equity, PEG Ratio. Debt-to-equity of 1.53 is elevated, increasing financial risk.

Key Dynamics to Monitor

MRK profiles as a value stock while WW is a turnaround play — different risk/reward profiles.

WW carries more volatility with a beta of 1.06 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

WW scores higher overall (39/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

WW International, Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

WW International, Inc. offers worldwide weight management products and services. The company is headquartered in New York, New York.

Visit Website →

Want to dig deeper into these stocks?